Vertex Pharmaceuticals
Jun 8, 2017
PDF

Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors

BOSTON--(BUSINESS WIRE)-- Shareholders of Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today elected Alan M. Garber, M.D., Ph.D. as an independent member of its board of directors. Dr. Garber is Provost of Harvard University, the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences, a Professor of Public Policy in the Harvard Kennedy School of Government, and a Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health.

"We are delighted that Alan is joining the Vertex Board. He brings both his deep experience as an academic physician as well as his expertise in health economics and the complexities of our healthcare system to Vertex," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "His insights and expertise will be invaluable as we continue to deliver on our mission of bringing transformative medicines to more people with cystic fibrosis and other serious diseases."

"I am pleased to join the board of an organization that endeavors to discover and deliver new medicines to treat life-threatening diseases," said Dr. Garber. "As a physician-researcher, I look forward to working together to improve the lives of people around the world."

Prior to joining Harvard in 2011, Dr. Garber was the Henry J. Kaiser Jr. Professor, a Professor of Medicine, and a Professor (by courtesy) of Economics, Health Research and Policy, and of Economics in the Graduate School of Business at Stanford University. He is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society of Clinical Investigation, the Association of American Physicians and the Board on Science, Technology, and Economic Policy at the National Academies. Dr. Garber is also a Fellow of the American College of Physicians and the Royal College of Physicians and a Research Associate with the National Bureau of Economic Research. He also has served as a member of the National Advisory Council on Aging at the National Institutes of Health, the Board of Health Advisers of the Congressional Budget Office and Chair of the Medicare Evidence Development and Coverage Advisory Committee at the Centers for Medicare and Medicaid Services.

Dr. Garber holds an A.B. summa cum laude, an A.M. and a Ph.D. in Economics from Harvard University, as well as an M.D. with research honors from Stanford University.

About Vertex
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.

Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For seven years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. For additional information and the latest updates from the company, please visit www.vrtx.com.

(VRTX-GEN)

Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, +1 617-341-6108
or
Eric Rojas, +1 617-961-7205
or
Zach Barber, +1 617-341-6470
or
Media:
mediainfo@vrtx.com
North America: +1 617-341-6992
or
Europe & Australia: +44 20 3204 5275

Source: Vertex Pharmaceuticals Incorporated

News Provided by Acquire Media